Glioblastoma multiforme is one of the most malignant brain tumors with an extremely poor prognosis. The average survival time for patients is only 12-18 months, and only 5 percent of patients survive longer than five years.
Recent studies have shown that in rapidly growing forms of glioblastoma multiforme, high expression of the PD-L1 protein found on the surface of some tumor cells and immune cells is observed. This protein acts as a "brake" on the immune system, and its blockade may allow the body to activate to fight the tumor.
PD-L1 activity can be blocked by modern immune drugs, but confirmation of the presence of this molecular target in the body is necessary before their use in a patient. To date, PD-L1 levels in brain tumors have only been assessed by biopsy, which is an invasive procedure and, in addition, provides only a snapshot of PD-L1 protein expression in the tumor and its microenvironment. Moreover, due to the high risks associated with biopsy, especially in the case of glioblastoma multiforme, these procedures are rarel...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
